Literature DB >> 17688669

Serum granulysin level as a novel prognostic marker in patients with gastric carcinoma.

Susumu Saigusa1, Takashi Ichikura, Hironori Tsujimoto, Hidekazu Sugasawa, Takashi Majima, Nobuaki Kawarabayashi, Kentaro Chochi, Satoshi Ono, Manabu Kinoshita, Shuhji Seki, Kazuyuki Ogawa, Hidetaka Mochizuki.   

Abstract

BACKGROUND: Granulysin is a cytolytic molecule present in human cytotoxic T cells and natural killer cell granules, and plays a key role in the cell-mediated immunity against tumor and infection. However, few studies have estimated serum granulysin concentrations in patients with solid or hematological malignancies.
METHODS: Peripheral blood samples were taken from patients with gastric carcinoma preoperatively and from healthy volunteers. Serum and tumor tissue granulysin concentrations were measured using a granulysin-specific ELISA kit in order to assess its prognostic value.
RESULTS: Both serum and tumor tissue granulysin concentrations were higher in patients with stage II or III gastric cancer and lower in patients with stage IV disease as compared to healthy controls. The low preoperative granulysin levels were associated with more frequent hepatic and peritoneal metastases, and with a poor outcome of the curative gastrectomy.
CONCLUSIONS: Preoperative serum granulysin levels reflect the status of cell-mediated immunity in patients with gastric carcinoma. It has significance as a prognostic determinant following a curative resection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688669     DOI: 10.1111/j.1440-1746.2006.04796.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  In vivo potential of recombinant granulysin against human tumors.

Authors:  Sameer Al-Wasaby; Diego de Miguel; Adriana Aporta; Javier Naval; Blanca Conde; Luis Martínez-Lostao; Alberto Anel
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

2.  Elevated serum granulysin and its clinical relevance in mature NK-cell neoplasms.

Authors:  Nodoka Sekiguchi; Naoko Asano; Toshiro Ito; Kayoko Momose; Masanobu Momose; Fumihiro Ishida
Journal:  Int J Hematol       Date:  2012-08-14       Impact factor: 2.490

3.  Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin.

Authors:  Poonam Tewary; De Yang; Gonzalo de la Rosa; Yana Li; Michael W Finn; Alan M Krensky; Carol Clayberger; Joost J Oppenheim
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

4.  Increased granulysin expression in peripheral blood cells of patients with primary biliary cirrhosis and its clinical implications.

Authors:  Cheng Qian; Sunxiao Chen; Dingkang Yao; Chuanyong Wu; Tingwang Jiang; Jinshan Ke; Ye Zhou; Mingli Gu; Bo Chen; Anmei Deng; Renqian Zhong
Journal:  J Clin Immunol       Date:  2008-06-28       Impact factor: 8.317

5.  15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity.

Authors:  Carol Clayberger; Michael W Finn; Tianhong Wang; Reena Saini; Christine Wilson; Valarie A Barr; Marianna Sabatino; Luciano Castiello; David Stroncek; Alan M Krensky
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

Review 6.  Biology and clinical relevance of granulysin.

Authors:  A M Krensky; C Clayberger
Journal:  Tissue Antigens       Date:  2009-03

7.  Granulysin expressed in a humanized mouse model induces apoptotic cell death and suppresses tumorigenicity.

Authors:  Ya-Wen Hsiao; Tsung-Ching Lai; Yu-Hsiang Lin; Chia-Yi Su; Jih-Jong Lee; Albert Taiching Liao; Yuan-Feng Lin; Shu-Chen Hsieh; Alexander T H Wu; Michael Hsiao
Journal:  Oncotarget       Date:  2016-08-22

8.  Granulysin as a novel factor for the prognosis of the clinical course of chickenpox.

Authors:  R Baljic; R Gojak; H Konjo; M Hukic
Journal:  Epidemiol Infect       Date:  2018-04-10       Impact factor: 4.434

Review 9.  Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer.

Authors:  Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; Ángel R Payer; Segundo Gonzalez; Alejandro López-Soto
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.